Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Rhea-AI Summary

Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor agonist:

1. Lean loss ratio of only 21.9%, indicating excellent preservation of lean mass.
2. Even better lean mass preservation in subjects aged 60+, with a lean loss ratio of 19.9%.
3. 25.6% reduction in visceral adipose tissue (VAT) at the 2.4mg dose, compared to 20.1% loss in subcutaneous adipose tissue.

These results suggest pemvidutide's potential in reducing fall and fracture risks, especially in older adults, while also lowering cardiovascular disease risk through VAT reduction.

Positive

• Pemvidutide showed a lean loss ratio of only 21.9%, indicating excellent preservation of lean mass
• Better lean mass preservation in subjects aged 60+, with a lean loss ratio of 19.9%
• 25.6% reduction in visceral adipose tissue (VAT) at the 2.4mg dose, potentially lowering cardiovascular disease risk
• Pemvidutide demonstrated superior lean mass preservation compared to historical diet and exercise results

Negative

• None.

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass

Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures

Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48

GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).

In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%. Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was only 19.9%. In addition to lean mass preservation, there was a preferential reduction of VAT, the adipose tissue associated with cardiovascular risk. At the 2.4mg dose of pemvidutide, VAT was reduced by 25.6% at Week 48 compared to a 20.1% loss in subcutaneous adipose tissue.

“Preservation of lean mass may reduce risk of falls and fractures, development of co-morbidities, and rates of all-cause mortality, particularly in individuals over the age of 60,” said Scott Harris, M.D., Chief Medical Officer of Altimmune. “Given the breadth and diversity of the obesity patient population, there has been growing attention given to the quality of weight loss. Our data demonstrates pemvidutide’s class-leading lean mass preservation, superior to that reported historically with diet and exercise. The robust reductions in VAT would also be expected to be associated with a lower risk of cardiovascular disease.”

About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

FAQ

What were the key findings of Altimmune's Phase 2 MRI-based body composition sub-study for pemvidutide (ALT)?

The key findings were a lean loss ratio of 21.9%, better lean mass preservation in subjects aged 60+ (19.9% lean loss ratio), and a 25.6% reduction in visceral adipose tissue at the 2.4mg dose of pemvidutide.

How does pemvidutide's lean mass preservation compare to other methods for ALT stock?

According to Altimmune, pemvidutide demonstrated class-leading lean mass preservation, superior to that reported historically with diet and exercise.

What potential benefits does pemvidutide (ALT) offer for older adults based on the Phase 2 study results?

Pemvidutide showed better lean mass preservation in subjects aged 60+, potentially reducing the risk of falls, fractures, and development of co-morbidities in this population.

How might the reduction in visceral adipose tissue (VAT) impact cardiovascular risk for pemvidutide (ALT) users?

The 25.6% reduction in VAT at the 2.4mg dose of pemvidutide is expected to be associated with a lower risk of cardiovascular disease.